Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
Authors
Keywords
Breast cancer, Triple-negative breast cancer, Intrinsic subtype, Gene expression profiling, Targeted therapies, Immune checkpoint inhibitors
Journal
PATHOLOGY & ONCOLOGY RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2017-09-14
DOI
10.1007/s12253-017-0307-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
- (2017) D. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.
- (2017) A. Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) G. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
- (2017) A. Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.
- (2017) D. D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2.
- (2017) A. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
- (2017) A. M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
- (2016) Chris Twelves et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
- (2015) H. R. Ali et al. ANNALS OF ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival
- (2015) Elisabeth Christine Inwald et al. BREAST CANCER RESEARCH AND TREATMENT
- Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
- (2015) Olivier Trédan et al. Clinical Breast Cancer
- Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer
- (2015) Antonella De Luca et al. Expert Opinion on Drug Metabolism & Toxicology
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
- (2015) Sara M. Tolaney et al. INVESTIGATIONAL NEW DRUGS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
- (2015) J. Watkins et al. Cancer Discovery
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
- (2014) Jasmeet Chadha Singh et al. BREAST CANCER RESEARCH
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Subtyping of triple-negative breast cancer: Implications for therapy
- (2014) Vandana G. Abramson et al. CANCER
- Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
- (2014) IA Mayer et al. CANCER RESEARCH
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Complexities of androgen receptor signalling in breast cancer
- (2014) Keely M McNamara et al. ENDOCRINE-RELATED CANCER
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
- (2014) S. D. Brown et al. GENOME RESEARCH
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
- (2014) Renaud Sabatier et al. Molecular Cancer
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
- (2014) Bob Li et al. Journal of Clinical Medicine
- BRCAness: a deeper insight into basal-like breast tumors
- (2013) S. De Summa et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition
- (2013) Hans-Peter Sinn et al. Breast Care
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
- (2013) A. Prat et al. ONCOLOGIST
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
- (2012) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
- (2012) MIAO LIU et al. Oncology Letters
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Endocrine Therapy of Breast Cancer
- (2011) F. Lumachi et al. CURRENT MEDICINAL CHEMISTRY
- Surgery in metastatic breast cancer: Patients with a favorable profile seem to have the most benefit from surgery
- (2011) Z.M. Rashaan et al. EJSO
- Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
- (2011) D. Koeberle et al. ENDOCRINE-RELATED CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Reputation and Precedent in the Bevacizumab Decision
- (2011) Daniel Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between breast cancer subtypes and response to neoadjuvant anastrozole
- (2011) Anita K. Dunbier et al. STEROIDS
- Stage IV breast cancer in the era of targeted therapy
- (2010) Heather B. Neuman et al. CANCER
- Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer
- (2010) Rupal Ramakrishnan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.
- (2010) L. Carey et al. CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast
- (2010) Felicia Marginean et al. MODERN PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
- (2009) B. T. Hennessy et al. CANCER RESEARCH
- Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
- (2009) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
- (2008) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More